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Wnt5A Activates the Calpain-Mediated Cleavage of
Filamin A
Michael P. O’Connell1,6, Jennifer L. Fiori2,6, Katherine M. Baugher1, Fred E. Indig3, Amanda D. French1,
Tura C. Camilli1, Brittany P. Frank3, Rachel Earley3, Keith S. Hoek4, Joanne H. Hasskamp5, E. George Elias5,
Dennis D. Taub1, Michel Bernier2 and Ashani T. Weeraratna1
We have previously shown that Wnt5A and ROR2, an orphan tyrosine kinase receptor, interact to mediate
melanoma cell motility. In other cell types, this can occur through the interaction of ROR2 with the cytoskeletal
protein filamin A. Here, we found that filamin A protein levels correlated with Wnt5A levels in melanoma cells.
Small interfering RNA (siRNA) knockdown of WNT5A decreased filamin A expression. Knockdown of filamin A
also corresponded to a decrease in melanoma cell motility. In metastatic cells, filamin A expression was
predominant in the cytoplasm, which western analysis indicated was due to the cleavage of filamin A in these
cells. Treatment of nonmetastatic melanoma cells with recombinant Wnt5A increased filamin A cleavage, and
this could be prevented by the knockdown of ROR2 expression. Further, BAPTA-AM chelation of intracellular
calcium also inhibited filamin A cleavage, leading to the hypothesis that Wnt5A/ROR2 signaling could cleave
filamin A through activation of calcium-activated proteases, such as calpains. Indeed, WNT5A knockdown
decreased calpain 1 expression, and by inhibiting calpain 1 either pharmacologically or using siRNA, it
decreased cell motility. Our results indicate that Wnt5A activates calpain-1, leading to the cleavage of filamin A,
which results in a remodeling of the cytoskeleton and an increase in melanoma cell motility.
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INTRODUCTION
Several recent studies have shown the upregulation of key
metastatic markers during the progression of melanoma and
have provided potential molecular targets (Bittner et al.,
2000; Clark et al., 2000; Weeraratna, 2003; Smith et al.,
2004). One such marker is Wnt5A, a member of the
noncanonical Wnt pathway, which has been implicated in
the pathogenesis of human cancer (Weeraratna et al., 2002;
Kurayoshi et al., 2006; Fernandez-Cobo et al., 2007;
MacLeod et al., 2007; Ripka et al., 2007). Activation of the
Wnt5A pathway leads to the release of calcium from
intracellular stores and to the upregulation of target proteins,
such as protein kinase C (PKC). In melanoma, upregulation of
Wnt5A increases cell invasion (Weeraratna et al., 2002). We
have recently shown that this increased invasiveness is due,
in part, to an epithelial-to-mesenchymal transition, accom-
panied by the upregulation of Snail and Vimentin (Dis-
sanayake et al., 2007). These findings were consistent with
our previous data that showed that Wnt5A overexpression
can cause reorganization of the actin cytoskeleton (Weerar-
atna et al., 2002).
The actin cytoskeleton consists of pools of globular
monomeric actin (G-actin) that can reversibly polymerize
into filamentous actin (F-actin), thus resulting in alterations in
the viscosity, elasticity, and mechanical resistance of the cell
(Popowicz et al., 2006). Bundling of actin into filopodia
(parallel bundles of actin filaments and associated proteins) is
important for directional motility and adhesion of cells
(Gupton and Gertler, 2007). Recently, filamin A, a scaffolding
protein that is part of a family of nonmuscle actin-binding
proteins, was shown to be required for filopodia formation,
through actin reorganization (Nishita et al., 2006). Filamin A
exists in a dimerized form, containing two hinge regions,
which are putative target sites for calpain cleavage (Feng and
Walsh, 2004). Calpains are calcium-dependent cysteine-
proteases involved in cytoskeleton remodeling and motility
(Potter et al., 1998), and of the 13 known calpains, only
calpains 1 and 2 are considered as ubiquitous calpains
(Glading et al., 2002). Reduced cell migration and disruption
of the actin cytoskeleton have been observed in calpain-
deficient embryonic fibroblasts (Dourdin et al., 2001).
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Interestingly, calpain 3 has been shown to be dysregulated in
melanoma, moving from the nuclei of non-neoplastic cells to
the cytoplasm of malignant cells (Weeraratna et al., 2004).
Filamin A has been shown to mediate Wnt5A-induced cell
migration through its interaction with the orphan tyrosine
kinase receptor, ROR2 (Nishita et al., 2006). The suppression
of either ROR2- or filamin A-induced filopodia inhibited cell
migration mediated by Wnt5A. As Wnt5A has been shown to
be an important mediator of melanoma progression, we
investigated the relationship between filamin A and Wnt5A in
metastatic melanoma.
RESULTS
Filamin A expression is increased in Wnt5A-high melanoma cell
lines
Highly metastatic melanoma cells show increased levels of
Wnt5A and PO4-PKC (Weeraratna et al., 2002; Dissanayake
et al., 2007). To determine if filamin A was elevated in
melanoma cell lines with high Wnt5A and increased
invasiveness, we examined the mRNA and protein levels of
filamin A compared with Wnt5A in melanoma cell lines of
differing metastatic potential. In a recent study, Hoek et al
(2006) performed gene expression profiling studies on a large
set of melanoma samples (known as the Mannheim data set).
These samples were cell lines created from primary
melanoma biopsies. Gene expression profiling data showed
that these melanomas could be separated into three dominant
groups of cell lines (cohorts A, B, and C). These groups could
be characterized by their microphthalmia-associated tran-
scription factor status, motility, and proliferation. Of these,
cohort A and, to a lesser extent, Cohort B consisted of highly
proliferative melanoma cells with low metastatic potential,
and cohort C consisted of weakly proliferative cells with high
metastatic potential. Analysis of the Mannheim data set
showed that WNT5A is dramatically upregulated in cohort C
as compared with cohorts A and B (Figure 1a). Bars shown
are an average of all samples in each cohort. Filamin A
(FLNA) mRNA was also increased in cohort C, although not
as dramatically as WNT5A (Figure 1b). Western blot analysis
was used to validate these observations in a second set of
melanoma cell lines derived from patient samples, and
showed a positive correlation between filamin A and Wnt5A
protein expression, in 8 out of 10 cell lines (Figure 1c).
We have previously characterized a panel of melanoma
cell lines on the basis of their Wnt5A status, PKC activity and
invasive capacity determined that high Wnt5A and PKC
correlate with increased metastatic capacity (Weeraratna
et al., 2002; Dissanayake et al., 2007). We used real-time
PCR to determine the correlation between FLNA mRNA and
WNT5A mRNA. In these lines, the expression of FLNAmRNA
was increased in lines with high WNT5A expression, and
thus increased invasive capacity (Figure 2a). Filamin A
protein expression was also increased in cells with Wnt5A
and high levels of PO4-PKC (Figure 2b). Treatment of Wnt5A-
low G-361 cells with recombinant Wnt5A led to an increase
in filamin A protein levels (Figure 2c). To determine whether
downregulation of Wnt5A expression affects the levels of
filamin A, small interfering RNA (siRNA) targeted against
WNT5A was used. Treatment of the high Wnt5A-expressing
cell line M93-047 with WNT5A siRNA resulted in a
significant decrease in filamin A protein levels, concomitant
with a reduction in Wnt5A expression (Figure 2d). These
results show a positive correlation between the levels of
Wnt5A and filamin A in metastatic melanoma cells, but it is
unclear if Wnt5A directly regulates filamin A, or if an
intermediate step is required.
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Figure 1. Filamin A expression is increased in primary melanoma cell lines with high Wnt5A expression. (a) WNT5A and (b) FLNA mRNA expression in the
three cohorts of the Mannheim data set. Cohorts A (n¼ 19) and B (n¼ 10) were considered low metastatic cell lines, whereas cohort C (n¼ 16) was highly
metastatic. Their metastasis rates inversely correlate with their proliferation as indicated in the table below the graphs. FLNA was significantly correlated with
WNT5A (**Po0.01). Bars represent averages of all patients in each cohort. (c) Western blot analysis was performed on 10 melanoma patient cell lines to detect
filamin A and Wnt5A, and confirmed that filamin A protein expression and Wnt5A expression are correlated at the protein level as well. b-Tubulin was used as a
loading control.
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FLNA knockdown reduces melanoma cell motility
Filamin A has been shown to be essential for filopodia
formation, an important event in the motility and migration of
various cell types. To determine if a reduction in filamin A
could lead to decreased motility in melanoma cells, cells
were transfected with siRNA against FLNA, and knockdown
of filamin A was observed at 48 hours (Figure 3a). After
48 hours of transfection with filamin A siRNA and negative
control siRNA, cells were subjected to a wound-healing
assay. In highly invasive M93-047 cells transfected with
control siRNA, the wound closed within 24 hours. Knock-
down of filamin A prevented closure of the wound (Figure
3b). Low Wnt5A-expressing G-361 cells, when transfected
with negative-control siRNA, usually take more than 72 hours
to completely heal a scratch wound (Figure 3c). When these
negative control-siRNA transfected cells were treated with
recombinant Wnt5A, the wound was completely healed by
48 hours (Figure 3c). Similar to negative control-siRNA-
transfected cells, G-361 cells treated with FLNA siRNA alone
also remained open at 48 hours. Subsequent treatment of
FLNA siRNA-transfected cells with recombinant Wnt5A
increased motility slightly, but did not fully rescue the effects
of filamin A silencing (Figure 3c). Taken together, these
results show an important role for filamin A in melanoma cell
motility and Wnt5A-induced cell migration.
Wnt5A affects the subcellular distribution of filamin A
One of the key steps in the acquisition of the metastatic
phenotype is the reorganization of the cytoskeleton. Wnt5A
overexpression has been shown to affect the expression and
organization of cytoskeletal molecules, such as actin (Weerar-
atna et al., 2002). We used immunofluorescent analysis to
determine whether Wnt5A expression could similarly affect the
subcellular distribution of filamin A. In low Wnt5A-expressing
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Figure 2. Wnt5A expression affects that of filamin A. (a) Real-time PCR
analysis of WNT5A and FLNA mRNA in G-361, UACC903, M93-047, and
UACC647 cell lines, normalized to 18S levels. Error bars are represented as
SEM, with values of *Po0.05 and **Po0.01. In G361 cells with low
metastatic capacity, WNT5A and FLNA levels are low as compared with the
other three metastatic cell lines. (b) Total protein was isolated for western blot
analysis of filamin A, PO4-PKC, and Wnt5A in all cell lines. Again, G361 cells
express lower levels of all of these proteins, but the expression of filamin A
and Wnt5A can be increased significantly upon rWnt5A treatment. (c) High
Wnt5A-expressing M93-047 cells were transfected with either control (CTRL)
or WNT5A siRNA for 48 hours. (d) Total protein was isolated for western blot
analysis of Wnt5A and filamin A expression, and showed decreases in filamin
A occurring upon Wnt5A knockdown. b-Tubulin was used as a loading
control.
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Figure 3. Filamin A is required for motility of melanoma cell lines. (a) M93-
047 cells were transfected with control or FLNA siRNA for 48 hours. Total
protein was isolated for western blot analysis of filamin A. b-Tubulin was used
as a loading control. (b) Highly metastatic M93-047 cells were transfected
with control or FLNA siRNA for 48 hours and then subjected to a wound-
healing assay for 24 hours. Images were taken until closure of the scratch
wound (24 hours), and FLNA knockdown inhibited the motility of melanoma
cells. (c) Low metastatic G-361 cells were transfected with control or FLNA
siRNA for 48 hours, and then left untreated or treated with recombinant
Wnt5A for the duration of the wound-healing assay (48 hours). Wnt5A
treatment could not completely rescue the decrease in motility upon FLNA
knockdown. Images were taken until closure of the scratch (48 hours).
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cells (G-361), filamin A was primarily localized near the
plasma membrane (Figure 4a), whereas in cells with higher
levels of Wnt5A (M93-047 and UACC647), there was an
increase in cytoplasmic filamin A (Figure 4a). Addition of
recombinant Wnt5A to G-361 cells resulted in an increase in
the expression of filamin A in the cytoplasm (Figure 4b).
This observation raised the question of whether the
cytoplasmic localization of filamin A upon Wnt5A treatment
could be due to its cleavage by cellular proteases. To
investigate this possibility, cell lysates were analyzed using
commercial monoclonal antibodies that recognize either the
N- or C-terminal domain of filamin A. Filamin A contains two
hinge regions (Gorlin et al., 1990), and cleavage at hinge 1
generates a 190 kDa fragment that can be detected using an
antibody that recognizes the N-terminal of this protein.
Cleavage at hinge 2 results in a B90 kDa fragment, which
can be detected with an antibody directed against the C-
terminal. In low-Wnt5A, nonmetastatic G361 cells, there is
little cleavage at either hinge 1 or hinge 2 as compared with
the highly metastatic lines (Figure 4c). However, treatment of
G-361 cells with recombinant Wnt5A increased the cleavage
of filamin A in a dose-dependent manner (Figure 4d). These
results indicate that cleavage of filamin A occurs at both
hinge regions and is inducible by Wnt5A, which may explain
the intracellular redistribution of filamin A in response to
Wnt5A treatment.
Cleavage of filamin A is mediated by calpain 1 in melanoma cell
lines
Calpains are calcium-dependent proteases that can cleave
filamin A at both hinge regions (Loy et al., 2003). At present,
there are 13 known human calpains (CAPN1–7, 9–11, 13, and
15), but only calpains 1 and 2 are considered as ubiquitous
(Glading et al., 2002). We show here that Wnt5A promotes
cleavage of filamin A. It has been reported previously that
Wnt5A can increase the intracellular concentrations of
calcium (reviewed by Ku¨hl et al., 2000). In addition, we
have recently shown that Wnt5A requires ROR2 to activate
the Ca2þ /PKC pathway and mediate the motility of melano-
ma cells (O’Connell et al., unpublished data). We hypothe-
sized that Wnt5A signaling through ROR2 increases calcium
release from the endoplasmic reticulum, thereby activating
calpain, which in turn cleaves filamin (Figure 5a). We tested
the first step in this hypothesis by knocking down ROR2 using
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Figure 4. Wnt5A increases filamin A cleavage. (a) The expression and localization of filamin A (red) was examined in melanoma cell lines of differing metastatic
potential using immunofluorescent confocal microscopy. Filamin A is found in a regular pattern around the periphery of the cell in G361 cells (low metastatic
potential), but is more cytoplasmic and irregular in the cell lines with a higher metastatic potential. (b) Treatment of G-361 cells with recombinant Wnt5A for
16 hours resulted in a redistribution of filamin A to the cytoplasm of the cells akin to the lines with higher metastatic capacity. Scale bar¼20 mm. (c) Total protein
lysates from G-361, UACC903, M93-047, and UACC647 cell lines were analyzed by western blot for the presence of filamin A cleavage fragments. Filamin A
cleavage fragments were identified as 190 kDa (N-terminal) and 90 kDa (C-terminal) bands, and cleavage was indeed increased in cell lines with higher
metastatic capacity. b-Tubulin was used as a loading control. (d) G-361 cells were treated with increasing amounts of recombinant Wnt5A for 16 hours and total
protein was isolated for western blot analysis of the 190 and 90 kDa N-terminal cleavage fragment. b-Tubulin was used as a loading control.
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siRNA. ROR2 knockdown in Wnt5A-high cells resulted in a
decrease in filamin A cleavage (Figure 5b). The use of 1,2-
Bis(2-aminophonoxy)ethane-N,N,N0,N0-tetraacetic acid tetra-
kis-(acetoxymethylester) (BAPTA-AM) as a calcium chelator
in these cells also decreased filamin cleavage (Figure 5c),
implying that both ROR2 and calcium are required for
Wnt5A-mediated filamin A cleavage, potentially through the
activation of calpains. To investigate this possibility, en-
dogenous mRNA levels of several calpains were determined
in low and high Wnt5A-expressing melanoma cell lines using
real-time PCR (data not shown). CAPN1 and 2 were most
abundantly expressed at the mRNA level. Western analysis
showed that, of these, only CAPN1 protein levels correlated
with Wnt5A expression (Figure 5d), and that the knockdown
of WNT5A resulted in a decrease in CAPN1 (Figure 5e).
Next, we investigated the effect of a cell-permeable
calpain inhibitor (calpain inhibitor III) on the cleavage of
filamin A in Wnt5A-high cells. Treatment of cells with
calpain inhibitor for 24 hours caused a marked reduction in
filamin A fragmentation (Figure 5f). Wnt5A levels were
unaffected as would be expected, if calpain signaling is truly
downstream of Wnt5A. To determine whether cellular
WNT
5A
ROR2
PIP2
IP3
CAPN
Cleaved filamin
Filamin
ER
Ca2+
48 hours siRNA BAPTA-AM (μM)
CTRL ROR2
N-terminal
Filamin A
β-Tubulin β-Tubulin
0 2 10
N-terminal
Filamin A
G
-3
61
UA
CC
90
3
UA
CC
64
7
M
93
-0
47
Calpain 1
Calpain 1Calpain 2
β-Tubulin β-Tubulin
48 hours siRNA
CTRL WNT5A
Untreated
Calpain
inhibitor III
(10 μM)
Filamin Actin Merge
Calpain inhibitor III (μM)
0 0.5 1 10
Wnt5A
N-Term
Filamin A
β-Tubulin
Figure 5. Calpain 1 plays a role in Wnt5A-mediated cleavage of filamin A. (a) Schematic hypothesis of Wnt5A-mediated filamin A cleavage: Wnt5A binds to
ROR2 causing the intracellular release of calcium, which can increase calpain activity, resulting in an increase in filamin A cleavage. (b) SiRNA knockdown of
ROR2 prevents filamin A cleavage in Wnt5A-high cells. (c) BAPTA chelation of intracellular calcium decreases the levels of filamin A cleavage in a dose-
dependent manner. (d) Calpain 1, but not calpain 2, protein expression correlates with that of Wnt5A and, thus, to increased invasive potential. (e) Knockdown
of Wnt5A decreases calpain 1 expression. (f) M93-047 cells were treated with increasing concentrations of calpain inhibitor III. Western blot analysis of Wnt5A
and filamin A N-terminal cleavage (190 kDa) were performed, and showed that filamin A cleavage is attenuated in the presence of calpain inhibitor. b-Tubulin
was used as a loading control. (g) Treatment of M93-047 cells with 10mM of calpain inhibitor III results in a redistribution of filamin A (red staining) from the
cytosol to the periphery of the cell. In calpain-inhibitor-treated cells, filamin A also colocalizes with actin (green). Scale bar¼20 mm. All experiments shown
here were performed with multiple Wnt5A-high cell lines, but in the interest of space, only M93-047 data is shown.
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redistribution of filamin A could result from the inhibition of
calpain activity, indirect immunofluorescent analyses were
performed using the N-terminal filamin antibody. Cells were
costained for F-actin using Phalloidin. Filamin A immunor-
eactivity was observed throughout the cytoplasm of the cell,
and actin was polymerized at the leading edge of these highly
invasive cells (Figure 5g). Furthermore, there was almost no
colocalization of actin and filamin A (Figure 5g, white arrow,
Figure S1A). Upon pretreatment of these cells with calpain
inhibitor III, filamin A clearly colocalized with cortical actin
at the cell periphery (Figure 5g, yellow arrow, Figure S1B),
confirming that calpain cleavage is necessary for the
cytoplasmic redistribution of filamin A. Taken together, these
data indicate that Wnt5A signaling through ROR2 activates
calcium and is required for the expression and activation of
CAPN1, and the subsequent cleavage of filamin A.
Calpain inhibition reduces motility in melanoma cell lines
To determine if the cleavage of filamin A was necessary for
melanoma cell motility, wound healing assays were per-
formed in the presence or absence of calpain inhibitor III for
24 hours. The results clearly showed a dose-dependent
reduction in motility in the two Wnt5A-high lines M93-047
and UACC647 (Figure 6a). SiRNA-mediated gene silencing
was then used to specifically target CAPN1. This resulted in a
significant inhibition of CAPN1 expression as compared with
negative control siRNA (Figure 6b). Knockdown of CAPN1
expression delayed wound closure by several hours in both
M93-047 and UACC647 cell lines, when compared with
cells transfected with control siRNA (Figure 6c).
DISCUSSION
We have shown previously that Wnt5A increases melanoma
metastasis through increases in PKC and affects cytoskeletal
reorganization (Weeraratna et al., 2002; Dissanayake et al.,
2007). We have also shown recently that Wnt5A requires
ROR2 to signal effectively, and the knockdown of ROR2 can
abrogate Wnt5A-mediated melanoma cell motility (O’Con-
nell et al., unpublished data). In osteoblasts, ROR2 interacts
physically with filamin A (Flanagan et al., 2001). We show
here that Wnt5A signaling, through ROR2, can increase
filamin A expression. This interaction requires a mechanism
involving the activation of calcium-activated proteases,
specifically calpain 1, and to our knowledge this is
unreported previously. Wnt5A can increase both PKC activity
and the levels of intracellular calcium (Ku¨hl et al., 2000). We
have shown previously that other calcium-activated proteins
(such as calmodulin-activated kinase II) can be increased
upon increased Wnt5A signaling (Dissanayake et al., 2007).
Calpains are a family of calcium-dependent, non-lysosomal
cysteine proteases that cleave cytoskeletal proteins, such as
filamin A (Potter et al., 1998; Feng and Walsh, 2004). The
correlation between calpain 1 and Wnt5A protein expression
suggests that calpain 1 is a Wnt5A-inducible protein whose
upregulation may be responsible for the increased levels of
cleaved filamin A in response to Wnt5A signaling. We
propose that in nonmetastatic melanoma cells with little
Wnt5A signaling, where the levels of calcium are low,
calpain 1 signaling is minimal, whereas upon activation of the
Wnt5A/ROR2 signaling pathway, calcium influx increases and
calpain 1 becomes activated, resulting in the subsequent
cleavage of filamin A. This is supported by our data indicating
that filamin A cleavage can be inhibited by ROR2 siRNA, as
well as by chelation of calcium by BAPTA-AM. Furthermore,
we show that WNT5A knockdown decreases calpain 1
expression, and filamin A cleavage and expression.
Blocking calpain activity reduces melanoma cell motility,
possibly due to the lack of filamin A cleavage and ensuing
intracellular redistribution. These results support earlier
findings that calpain-mediated cleavage of cytoskeletal
proteins is essential for motility and invasiveness. For
example, it has been reported that calpains are required for
normal osteoclast function and that reduction of calpains
leads to a decrease in motility (Marzia et al., 2006). In renal
cell cancer, calpain 1 expression has been shown to correlate
with advanced disease and poorer outcome (Braun et al.,
1999). In melanoma, specifically, calpains have been shown
to be important in the degradation of p27kip1, the loss of
which is associated with poorer outcome for melanoma
(Delmas et al., 2003). Another interesting observation is that
calpains are involved also in regulating melanin biosynthesis,
potentially through the degradation of tyrosinase (Ohguchi
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et al., 2005). The reason that this is particularly intriguing is
that recent data from our laboratory suggest that Wnt5A
overexpression results in a decrease in both melanin
production and the expression of many markers associated
with melanogenesis (Dissanayake et al., 2008). Although we
show that at least some of these markers are regulated through
Wnt5A/PKC activation of STAT3, and subsequent STAT3-
mediated inhibition of the transcription factors PAX3 and
SOX10, not all melanogenic proteins are under the control of
these factors. It is probable that the Wnt5A-mediated activation
of calpain-1, and the subsequent degradation of other
melanogenic proteins, may also play a complementary role in
the regulation of melanogenesis. As many of the proteins
involved in melanogenesis (for example, MART-1, GP100) can
act as antigens for tumor-infiltrating immune cells (Kawakami
et al., 1998), the downregulation of these antigens by tumor
cells may result in increased tumor aggression.
To our knowledge, the findings that filamin A expression
correlates with levels of Wnt5A in melanoma cell lines and
that a reduction of filamin A decreases the metastatic
potential of these cells have not been reported previously.
Furthermore, Wnt5A can induce calpain-dependent cleavage
of filamin A, an essential step in promoting cell motility and
invasiveness in melanoma cell lines. Targeting Wnt5A in
conjunction with any of these downstream markers could
have significant implications for melanoma therapy.
MATERIALS AND METHODS
Analysis of the Mannheim data set
The Mannheim data is publicly available from NCBI’s gene
expression omnibus (www.ncbi.nlm.nih.gov/geo) under GEO Series
accession no. GSE4845. This data set was generated from microarray
analysis of 45 primary cultures of melanoma biopsies, using
Affymetrix HGU133 microarray chips. Analysis of the data set for
expression of WNT5A and FLNA was performed using a Student’s
two-tailed t-test (assuming equal variance) to determine statistical
significant between cohorts.
Cell culture
Cells were cultured in T-25 tissue culture flasks and expanded in
T-75 flasks (Corning, Corning, NY). UACC903, M93-047, UACC647,
and Franklin Square cell lines were maintained in RPMI (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitro-
gen), 100Uml1 penicillin and streptomycin, and 4mM L-glutamine.
G-361 cells were maintained in McCoy’s (Invitrogen) supplemented
with 10% fetal bovine serum, 100Uml1 penicillin and streptomy-
cin, and 4mM L-glutamine. All cell lines were cultured at 371C in 5%
CO2, and the medium was replaced every 2–3 days as needed.
Wnt5A and calpain inhibitor treatment
For experiments requiring treatment, cells were incubated with
50–200 ngml1 of recombinant mouse Wnt5A (R&D Systems,
Minneapolis, MN) for 16 hours or 0.5, 1, or 10 mM of calpain
inhibitor III (Sigma Aldrich, St. Louis, MO) for 24 hours.
siRNA transfection
Cells were transfected with high performance (HP)-validated
negative control (CTRL), FLNA, and CAPN1 siRNA (200 nmol,
Qiagen, Valencia, CA) using Lipofectamine (Invitrogen) for 48 hours
as described previously (Dissanayake et al., 2007). Sequences for
siRNA were as follows: CTRL: sense, r(UUCUCCGAACGUGUCG
UCACGU)dTdT; antisense, r(ACGUGACACGUUCGGAGAA)dTdT;
FLNA: sense, r(GGAAGAAGAUCCAGCAGAA)dTdT; antisense,
r(UUCUGCUGGAUCUUCUUCC)dGdG; CAPN1: sense, r(CCACG
GAACUGCUGUCAAA)dTdT; antisense, r(UUUGACAGCAGUUCC
GUGG)dGdG.
These siRNAs are designed with unequal stabilities of the 30 and
50 bases, to reduce the risk of off-target effects. Details can be found
at the Qiagen website: http://www1.qiagen.com/products/genesilen-
cing/hponguardsirnadesign.aspx.
Wound-healing assay
Cells were seeded at 1 105cells per well in 24-well plates coated
with fibronectin (BD Biosciences, San Jose, CA). Once confluent, a
200ml tip (PGC Scientifics) was heat-sealed, and one horizontal and
one vertical scratch was made. Images of the same field were taken
at 0, 12, 24, 48, and 72 hours, as required, on a light microscope
(Zeiss) using phased light at a gain of 1.
Immunofluorescence
Cells were seeded at 5 105cells per well (G-361) and 3 105cells
per well (UACC903 and M93-047) into one-well chamber slides (Lab-
Tek, Campbell, CA) and incubated overnight at 371C, 5% CO2, in a
humidified environment. Cells were fixed in ice-cold 95% methanol
for 20minutes at room temperature, washed in phosphate-buffered
saline, and blocked using sterile-filtered blocking buffer (0.2% Triton
X-100, 0.2% BSA, 0.2% casein, 0.2% gelatin, and 0.02% sodium
azide) for 1h at room temperature. Filamin A primary antibody (1:100,
RDI, Concord, MA) was added in blocking buffer and slides were
incubated overnight at 41C. Cells were then washed in phosphate-
buffered saline and treated with Alexa Fluor-555 secondary antibody
(1:1,000, Invitrogen) in blocking buffer for 1h at room temperature. For
F-actin staining, cells were fixed in 4% paraformaldehyde and stained
with Phalloidin-488 (Invitrogen). Next, cells were washed in
phosphate-buffered saline and mounted in Prolong Gold antifade
reagent containing 4,6-diamidino-2-phenylindole (Invitrogen) and
cured for 24hours at room temperature in the dark. Images were
taken using a Zeiss Meta 510 confocal microscope.
RNA extraction, cDNA synthesis, and real-time PCR
RNA was extracted using Trizol (Invitrogen) and an RNeasy Mini kit
(Qiagen), and from 1mg of RNA, cDNA was synthesized as
described previously (Dissanayake et al., 2007). Gene expression
was quantified using the SYBR green method of real-time PCR and
mRNA levels were compared with standard curves and normalized
to 18S mRNA following the absolute quantitation method. PCRs
were performed in triplicate with Universal 18S primers (Ambion,
Austin, TX) or 100 nM of each gene-specific primer. Primers are
included in Table S1. Real-time PCR was performed on an ABI Prism
7,300 sequence detection system using the following conditions:
501C for 2minutes, 951C for 10minutes, 40 cycles of 951C for
15 seconds, and 601C for 1minute.
SDS-PAGE and western blotting
Cells were lysed as described previously (Dissanayake et al., 2007). A
total of 50mg of protein was run on a 4–20% Tris-glycine gel
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(Invitrogen), transferred, and blocked as described previously (Dis-
sanayake et al., 2007). Primary antibodies were incubated overnight at
41C as follow: anti-filamin A (1:1,000, RDI), N-terminal anti-filamin A
(1:1,000, Chemicon, Billerica, MA), C-terminal anti-filamin A
(1:1,000, Chemicon), biotin-conjugated anti-Wnt5A (1:100, R&D
Systems), PO4-PKC (1:1,000, Cell Signaling, Danvers, MA), and b-
tubulin (1:1,000, Cell Signaling). Membranes were washed in TBST,
and the appropriate secondary antibody was added in 5% milk/TBST
for 1h at room temperature with agitation. Membrane was washed in
TBST and developed using ECL plus (Amersham Biosciences, GE
Healthsciences, Piscataway, NJ).
Densitometry
Images were saved as Tiff files, inverted, and integrated density was
analyzed. Densitometry was performed using ImageJ software (NIH)
and values were normalized to b-tubulin.
Statistical analysis
A Student’s t-test was performed when required in at least three
independent experiments. Significance was designated as *Po0.05
and **Po0.01.
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